Catalogo Articoli (Spogli Riviste)

OPAC HELP

Titolo:
ERYTHROCYTE THIOLMETHYLTRANSFERASE - ANOTHER FAILED MARKER FOR ALZHEIMERS AND PARKINSONS DISEASES
Autore:
HURWITZ A; HUBBLE JP; GLATT SL; KOLLER WC; POLLACK J;
Indirizzi:
UNIV KANSAS,MED CTR,DEPT MED,3901 RAINBOW BLVD KANSAS CITY KS 66160 UNIV KANSAS,MED CTR,DEPT NEUROL KANSAS CITY KS 66160
Titolo Testata:
Neurology
fascicolo: 10, volume: 45, anno: 1995,
pagine: 1903 - 1906
SICI:
0028-3878(1995)45:10<1903:ET-AFM>2.0.ZU;2-S
Fonte:
ISI
Lingua:
ENG
Soggetto:
THIOL METHYLTRANSFERASE; BIOCHEMICAL-PROPERTIES; XENOBIOTIC METABOLISM; MOTORNEURON DISEASE; INORGANIC SULFATE; S-METHYLATION; DIETHYLDITHIOCARBAMATE; NEUROTOXICITY; TOXICITY; CYSTEINE;
Tipo documento:
Article
Natura:
Periodico
Settore Disciplinare:
Science Citation Index Expanded
Citazioni:
48
Recensione:
Indirizzi per estratti:
Citazione:
A. Hurwitz et al., "ERYTHROCYTE THIOLMETHYLTRANSFERASE - ANOTHER FAILED MARKER FOR ALZHEIMERS AND PARKINSONS DISEASES", Neurology, 45(10), 1995, pp. 1903-1906

Abstract

There are reports that patients with Parkinson's disease (PD) and Alzheimer's disease (AD) have reduced levels of thiolmethyltransferase (TMT) in erythrocyte membranes. TMT methylates thiols and thiocarbamates, thereby reducing their toxicity. We examined TMT levels in erythrocytes from patients with PD and AD and from age-matched controls. Specific activities of TMT were 564 +/- 199 U/mg protein in PD (n = 32), 513+/- 118 in AD (n = 13), and 565 +/- 183 in controls (n = 35). There was no difference between any of the groups (p = 0.64). We failed to confirm TMT as a marker for neurodegenerative diseases or for this metabolic defect predisposing to susceptibility to neurotoxins.

ASDD Area Sistemi Dipartimentali e Documentali, Università di Bologna, Catalogo delle riviste ed altri periodici
Documento generato il 13/07/20 alle ore 05:21:49